Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 13/20 | 0.57 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.52 |
| ▸ | POLA1 | P09884 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25340327 | 0.90 | P2RY6 (0.55) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL1129337 | 0.85 | P2RY6 (0.60) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL150274 | 0.84 | P2RY6 (0.59) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL7745802 | 0.84 | P2RY6 (0.59) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL26676224 | 0.84 | P2RY6 (0.59) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL8441087 | 0.84 | P2RY6 (0.59) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL30225473 | 0.84 | P2RY6 (0.53) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL28293726 | 0.84 | P2RY6 (0.58) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL8441389 | 0.83 | P2RY6 (0.56) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL1129233 | 0.83 | P2RY6 (0.62) | P2RY6P2RY2P2RY4POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10125162-B2 | Methods for the development of vaccines based on oligosaccharide-oligonucleotide conjugates | BRANDEIS UNIVERSITY (US) | 2018-11-13 | — | — | US | disclosed |
| US-20160051690-A1 | METHODS FOR THE DEVELOPMENT OF VACCINES BASED ON OLIGOSACCHARIDE-OLIGONUCLEOTIDE CONJUGATES | UNIV BRANDEIS (US) | 2016-02-25 | — | — | US | disclosed |
| US-9080169-B2 | Methods for the development of vaccines based on oligosaccharide-oligonucleotide conjugates | BRANDEIS UNIVERSITY (US) | 2015-07-14 | — | — | US | disclosed |
| US-20130116417-A1 | Methods for the Development of Vaccines Based on Oligosaccharide-Oligonucleotide Conjugates | BRANDEIS UNIVERSITY (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10125162-B2 | Methods for the development of vaccines based on oligosaccharide-oligonucleotide conjugates | DDOST, STT3A, STT3B | P2RY6 4582/4885P2RY2 4792/4885P2RY4 4621/4885 |
| US-20130116417-A1 | Methods for the Development of Vaccines Based on Oligosaccharide-Oligonucleotide Conjugates | DDOST, STT3A, STT3B | P2RY6 4527/4885P2RY2 4785/4885P2RY4 4616/4885 |
| US-20160051690-A1 | METHODS FOR THE DEVELOPMENT OF VACCINES BASED ON OLIGOSACCHARIDE-OLIGONUCLEOTIDE CONJUGATES | DDOST, STT3A, STT3B | P2RY6 4582/4885P2RY2 4792/4885P2RY4 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.